QRL-201 - Dose 4 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1

2. Amyotrophic lateral sclerosis


Clinical trials : 645 Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05633459
(ClinicalTrials.gov)
December 16, 202221/11/2022A Study Evaluating the Safety and Tolerability of QRL-201 in ALSA Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: QRL-201 - Dose 1;Drug: QRL-201 - Dose 2;Drug: QRL-201 - Dose 3;Drug: QRL-201 - Dose 4;Drug: QRL-201 - Dose 5;Drug: QRL-201 - Dose 6;Drug: QRL-201 - Dose 7;Drug: QRL-201- Dose 8QurAlis CorporationNULLRecruiting18 Years80 YearsAll64Phase 1Canada